Lead Product(s): FX06
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FX06
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Assistance Publique Hopitaux de Paris
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Company has announced that the randomized, double-blind, placebo-controlled FX-COVID trial which is conducted by AP-HP (Assistance Publique – Hopitaux de Paris), is set up to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.